A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
Latest Information Update: 04 Dec 2024
At a glance
- Drugs RG 6341 (Primary)
- Indications Allergic asthma; Asthma; Chronic bronchitis; Chronic obstructive pulmonary disease; Cough
- Focus Therapeutic Use
- Sponsors Genentech
- 02 Dec 2024 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned End Date changed from 15 Sep 2024 to 20 Oct 2024.
- 19 Sep 2024 Planned primary completion date changed from 15 Sep 2024 to 20 Oct 2024.